Howe & Rusling Inc Bristol Myers Squibb CO Transaction History

Howe & Rusling Inc

$1.18 Billion
Q1 2025

A detailed history of Howe & Rusling Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Howe & Rusling Inc holds 8,128 shares of BMY stock, worth $374,050. This represents 0.04% of its overall portfolio holdings.

Number of Shares

8,128

Previous 8,128 -0.0%

Holding current value

$374,050

Previous $459,000 7.84%

% of portfolio

0.04%

Previous 0.04%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$51.92 - $59.94 $24,246 - $27,991	467 Added 6.1%	8,128 $459,000
Q3 2024 Nov 08, 2024	SELL	$39.66 - $51.75 $97,642 - $127,408	-2,462 Reduced 24.32%	7,661 $396,000
Q2 2024 Aug 13, 2024	SELL	$40.25 - $52.99 $18,152 - $23,898	-451 Reduced 4.27%	10,123 $420,000
Q1 2024 May 15, 2024	SELL	$47.98 - $54.4 $71,586 - $81,164	-1,492 Reduced 12.37%	10,574 $573,000
Q4 2023 Feb 05, 2024	SELL	$48.48 - $57.85 $77,471 - $92,444	-1,598 Reduced 11.69%	12,066 $619,000
Q3 2023 Nov 08, 2023	SELL	$57.89 - $64.73 $4.2 Million - $4.7 Million	-72,623 Reduced 84.16%	13,664 $793,000
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $1,274 - $1,414	-20 Reduced 0.02%	86,287 $5.52 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $18,267 - $20,719	-278 Reduced 0.32%	86,307 $5.98 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $2.44 Million - $2.89 Million	35,668 Added 70.05%	86,585 $6.23 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $3,499 - $2.07 Million	-26,923 Reduced 34.59%	50,917 $3.62 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $86,708 - $95,496	1,194 Added 1.56%	77,840 $5.99 Million
Q1 2022 May 10, 2022	BUY	$61.48 - $73.72 $64,369 - $77,184	1,047 Added 1.38%	76,646 $5.6 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $1.57 Million - $1.84 Million	-29,356 Reduced 27.97%	75,599 $4.71 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $66,092 - $77,419	-1,117 Reduced 1.05%	104,955 $6.21 Million
Q2 2021 Aug 13, 2021	SELL	$61.91 - $67.42 $1.63 Million - $1.78 Million	-26,375 Reduced 19.91%	106,072 $7.09 Million
Q1 2021 May 13, 2021	SELL	$59.34 - $66.74 $4.03 Million - $4.53 Million	-67,895 Reduced 33.89%	132,447 $8.36 Million
Q4 2020 Feb 08, 2021	SELL	$57.74 - $65.43 $39,782 - $45,081	-689 Reduced 0.34%	200,342 $12.4 Million
Q3 2020 Nov 06, 2020	SELL	$57.43 - $63.64 $1.74 Million - $1.93 Million	-30,276 Reduced 13.09%	201,031 $12.1 Million
Q2 2020 Jul 15, 2020	BUY	$54.82 - $64.09 $1.44 Million - $1.69 Million	26,316 Added 12.84%	231,307 $13.6 Million
Q1 2020 May 14, 2020	BUY	$46.4 - $67.43 $1.17 Million - $1.7 Million	25,204 Added 14.02%	204,991 $11.4 Million
Q4 2019 Feb 05, 2020	SELL	$49.21 - $64.19 $3.78 Million - $4.93 Million	-76,763 Reduced 29.92%	179,787 $11.5 Million
Q3 2019 Oct 31, 2019	BUY	$42.77 - $50.71 $117,959 - $139,858	2,758 Added 1.09%	256,550 $13 Million
Q2 2019 Aug 12, 2019	BUY	$44.62 - $49.34 $6.48 Million - $7.17 Million	145,228 Added 133.77%	253,792 $11.5 Million
Q1 2019 Apr 29, 2019	BUY	$45.12 - $53.8 $4.68 Million - $5.58 Million	103,721 Added 2141.67%	108,564 $5.18 Million
Q4 2018 Feb 04, 2019	SELL	$48.76 - $63.23 $21,210 - $27,505	-435 Reduced 8.24%	4,843 $252,000
Q3 2018 Nov 07, 2018	BUY	$55.19 - $62.25 $61,812 - $69,720	1,120 Added 26.94%	5,278 $328,000
Q2 2018 Jul 31, 2018	BUY	$50.53 - $62.98 $28,599 - $35,646	566 Added 15.76%	4,158 $230,000
Q1 2018 May 14, 2018	SELL	$59.92 - $68.98 $300,079 - $345,451	-5,008 Reduced 58.23%	3,592 $227,000
Q4 2017 Jan 24, 2018	SELL	$59.94 - $65.35 $29,190 - $31,825	-487 Reduced 5.36%	8,600 $527,000
Q3 2017 Oct 18, 2017	BUY	$55.23 - $63.74 $501,875 - $579,205	9,087	9,087 $579,000

Others Institutions Holding BMY

# of Institutions

2,670

Shares Held

1.64B

Call Options Held

22.5M

Put Options Held

25.3M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $97.8B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Howe & Rusling Inc, based on Form 13F filings with the SEC.

News

Stay updated on Howe & Rusling Inc with notifications on news.

Account